Inhibiting plasma kallikrein for hereditary angioedema prophylaxis
A Banerji, P Busse, M Shennak, W Lumry… - New England journal …, 2017 - Mass Medical Soc
Background Hereditary angioedema with C1 inhibitor deficiency is characterized by
recurrent, unpredictable swelling episodes caused by uncontrolled plasma kallikrein …
recurrent, unpredictable swelling episodes caused by uncontrolled plasma kallikrein …
Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial
Importance Current treatments for long-term prophylaxis in hereditary angioedema have
limitations. Objective To assess the efficacy of lanadelumab, a fully human monoclonal …
limitations. Objective To assess the efficacy of lanadelumab, a fully human monoclonal …
[HTML][HTML] Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema
E Aygören-Pürsün, A Bygum… - … England Journal of …, 2018 - Mass Medical Soc
Background Hereditary angioedema is a life-threatening illness caused by mutations in the
gene encoding C1 inhibitor (also called C1 esterase inhibitor) that lead to overactivation of …
gene encoding C1 inhibitor (also called C1 esterase inhibitor) that lead to overactivation of …
Ecallantide for the treatment of acute attacks in hereditary angioedema
M Cicardi, RJ Levy, DL McNeil, HH Li… - … England Journal of …, 2010 - Mass Medical Soc
Background Hereditary angioedema is a rare genetic disorder characterized by acute,
intermittent, and potentially life-threatening attacks of edema of the skin and mucosa. We …
intermittent, and potentially life-threatening attacks of edema of the skin and mucosa. We …
Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor
H Longhurst, M Cicardi, T Craig, K Bork… - New England journal …, 2017 - Mass Medical Soc
Background Hereditary angioedema is a disabling, potentially fatal condition caused by
deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use …
deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use …
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
Background Lanadelumab demonstrated efficacy in preventing hereditary angioedema
(HAE) attacks in the phase 3 HELP Study. Objective To assess time to onset of effect and …
(HAE) attacks in the phase 3 HELP Study. Objective To assess time to onset of effect and …
Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies
AL Sheffer, M Campion, RJ Levy, HH Li, PT Horn… - Journal of allergy and …, 2011 - Elsevier
Background Hereditary angioedema (HAE) is a rare disorder characterized by recurrent
angioedema attacks. Ecallantide, a novel plasma kallikrein inhibitor, inhibits production of …
angioedema attacks. Ecallantide, a novel plasma kallikrein inhibitor, inhibits production of …
Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor
L Schneider, W Lumry, A Vegh, AH Williams… - Journal of allergy and …, 2007 - Elsevier
BACKGROUND: Hereditary angioedema (HAE) is a rare, autosomal-dominant disorder
caused by C1 inhibitor gene mutation. Patients with HAE experience intermittent attacks of …
caused by C1 inhibitor gene mutation. Patients with HAE experience intermittent attacks of …
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a …
Background Hereditary angioedema is associated with dysregulation of the kallikrein–kinin
system. Factor XII (FXII) is a key initiator of the kallikrein–kinin system, which produces …
system. Factor XII (FXII) is a key initiator of the kallikrein–kinin system, which produces …
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled …
E Aygören-Pürsün, A Zanichelli, DM Cohn, M Cancian… - The Lancet, 2023 - thelancet.com
Background Guidelines recommend effective on-demand therapy for all individuals with
hereditary angioedema. We aimed to assess the novel oral plasma kallikrein inhibitor …
hereditary angioedema. We aimed to assess the novel oral plasma kallikrein inhibitor …